Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Q-linea AB ( (SE:QLINEA) ).
Q-linea AB’s Q3 2025 report highlights significant growth in their ASTar platform, with new contracts in the US, Italy, and Saudi Arabia, and increased demand for consumables. The company’s strategic partnerships with pharmaceutical firms aim to expand the ASTar menu, while internalizing consumable production reduces costs. Despite a setback in the ESTAR tender appeal, Q-linea’s pipeline is robust, driven by the discontinuation of the Pheno platform by a competitor. A rights issue of SEK 322 million is set to support their goal of breakeven by 2027, as they continue to focus on customer-centric and cost-efficient operations.
The most recent analyst rating on (SE:QLINEA) stock is a Hold with a SEK51.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
More about Q-linea AB
Q-linea AB operates in the medical technology industry, focusing on the development and commercialization of advanced systems for rapid antibiotic susceptibility testing (AST). Their primary product, the ASTar platform, is designed to enhance the speed and accuracy of diagnosing infections, with a market focus on healthcare facilities worldwide.
YTD Price Performance: -70.91%
Average Trading Volume: 13,005
Technical Sentiment Signal: Sell
Current Market Cap: SEK173.5M
See more data about QLINEA stock on TipRanks’ Stock Analysis page.
Trending Articles:
- RTO Doesn’t Always Mean RTO: Microsoft Stock (NASDAQ:MSFT) Notches Up as Salespeople Find Exemption
- This Was Not the First Bid: Warner Bros. Discovery Stock (NASDAQ:WBD) Gains as it Rejected Three Bids from Paramount So Far
- ‘Paramount Can Walk Away with Warner Bros.’ Say TD Cowen and Benchmark Analysts